
ICLUSIG® (ponatinib) May Help
ICLUSIG study results in Ph+ ALL
A study looked at the safety and efficacy of ICLUSIG in 32 adult patients whose Ph+ ALL was resistant or intolerant to 2 or more TKIs or that had the T315i mutation.
The study looked at 2 types of treatment responses to see how well ICLUSIG was working:
ICLUSIG was effective in Ph+ ALL
Side effects with ICLUSIG
Get details about potential side effects from clinical studies.